Please use this identifier to cite or link to this item:
http://hdl.handle.net/1942/35401
Title: | Photobiomodulation therapy for the prevention of acute radiation dermatitis in breast cancer patients undergoing hypofractioned whole‐breast irradiation (LABRA trial) | Authors: | ROBIJNS, Jolien LODEWIJCKX, Joy Van Bever, Leen Puts, Sofie Timmermans, An Noe, Leen Vanmechelen, Sofie Govers, Mieke Van de Werf, Evelyn MAES, Annelies BULENS, Paul MEBIS, Jeroen Claes, Stefan Pannekoeke, Luc |
Issue Date: | 2022 | Publisher: | WILEY | Source: | LASERS IN SURGERY AND MEDICINE; 54 (3) , p. 374-383 | Abstract: | Objectives To evaluate the efficacy of photobiomodulation therapy in breast cancer patients post-lumpectomy undergoing hypofractionated whole-breast irradiation (HF-WBI) for the prevention and management of acute radiodermatitis (ARD). Materials and Methods A randomized, multicentric clinical trial (LABRA trial, NCT03924011) was set up at the Limburg Oncology Center, including the Jessa Hospital (Hasselt, BE) and Ziekenhuis Oost-Limburg (Genk, BE). A total of 71 breast cancer patients planned to undergo HF-WBI were randomized to one of the two study arms: the control group (n = 32) or the PBM group (n = 39). The PBM group received the standard institutional skincare combined with PBM (2x/week) during the complete radiotherapy (RT) course. Patients in the control group received the standard skincare combined with placebo treatment (2x/week). Patients' skin reactions were evaluated weekly during the RT treatment by using the modified version of the Radiation Therapy Oncology Group (RTOG) criteria. Results At week 3 of RT, one patient presented a grade 2 and one patient a grade 3 skin reaction in the control group, while in the PBM group, all patients still presented grade 1 ARD. At the final RT session 28% of the patients presenting grade 2-3 ARD, while in the PBM group 10% presented grade 2 and no grade 3 ARD. PBM reduced the incidence of severe ARD by 18%. However, the difference was not significant (p = 0.053). Conclusion Based on the LABRA trial results, PBM seems not able to reduce the incidence of severe ARD in breast cancer patients undergoing HF-WBI. Research in a larger patient population is recommended. | Notes: | Robijns, J (corresponding author), Hasselt Univ, Fac Med & Life Sci, Martelarenlaan 42, B-3500 Hasselt, Belgium. Jolien.robijns@uhasselt.be |
Keywords: | acute radiodermatitis;breast cancer;dermatology;photobiomodulation therapy;radiotherapy;skin | Document URI: | http://hdl.handle.net/1942/35401 | ISSN: | 0196-8092 | e-ISSN: | 1096-9101 | DOI: | 10.1002/lsm.23475 | ISI #: | WOS:000693508200001 | Rights: | 2021 Wiley Periodicals LLC | Category: | A1 | Type: | Journal Contribution | Validations: | ecoom 2022 |
Appears in Collections: | Research publications |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
Lasers Surg Med - 2021 - Robijns - Photobiomodulation therapy for the prevention of acute radiation dermatitis in breast.pdf Restricted Access | Published version | 367.93 kB | Adobe PDF | View/Open Request a copy |
SCOPUSTM
Citations
16
checked on Aug 31, 2025
WEB OF SCIENCETM
Citations
12
checked on Aug 31, 2025
Google ScholarTM
Check
Altmetric
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.